In Part 1 of this Research Rundown, we try to wrap our heads around an evidence brief prepared for the US Department of Veterans Affairs (VA), entitled Hyperbaric Oxygen Therapy for Traumatic Brain Injury and or Post-Traumatic Stress Disorder. Highlights: The brief...
In this Research Rundown we review a study that investigates the use of hyperbaric oxygen therapy to treat military personnel. This study is a good example of the studies floating around that could be preventing our American Heroes from getting the help they need and...
In this Research Rundown we dive into a study that used hyperbaric oxygen therapy to treat animal subjects suffering from Post-Traumatic Stress Disorder (PTSD) associated with a Traumatic Brain Injury (TBI). Highlights: The study shows substantial evidence of HBOT...
In this Research Rundown we examine a TBI HBOT study that gets two thumbs up from our host, Edward diGirolamo. TBI (Traumatic Brain Injuries) is one of the leading causes of death and disability in the general population, with 25% of patients experiencing PCS...
A recent systematic review published in the journal Frontiers in Neurology discovered that hyperbaric oxygen therapy could be a very effective and safe therapy option for mild traumatic brain injuries (mTBI). The review was conducted by Dr. Paul G. Harch, a clinical...
Extivita RTP is finding success using hyperbaric oxygen therapy (HBOT) to treat veterans who suffer from post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Under Senate Bill 422, and in collaboration with The Community Foundation of NC East,...
Abstract Introduction: Hyperbaric oxygen therapy (HBOT) is a commonly used treatment for a variety of medical issues, including more than a dozen currently approved uses. However, there are alternative proposed uses that have significant implications among an active...
The Evidence Synthesis Program (ESP) Coordinating Center is responding to a request from the VA Health Services Research and Development Service for an update to the 2018 ESP evidence brief on the use of hyperbaric oxygen therapy (HBOT) to treat Veterans and...
Abstract: Persistent postconcussion syndrome (PPCS) after mild traumatic brain injury (mTBI) is a significant public health and military problem for which there is limited treatment evidence. The aim of this study was to determine whether forty 150 kPa hyperbaric...
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.
